Startups
Edit
http://parentprojectmd.org/
Parent Project Muscular Dystrophy (PPMD)
TrustedLast activity: 30.07.2026
Active
Parent Project Muscular Dystrophy (PPMD) is the largest most comprehensive nonprofit organization in the United States focused on finding a cure for Duchenne muscular dystrophy—our mission is to end Duchenne.
We invest deeply in treatments for this generation of people affected by Duchenne and in research that will benefit future generations. We advocate in Washington, DC, and have secured hundreds of millions of dollars in funding. We demand optimal care, and we strengthen, unite and educate the global Duchenne community.
Everything we do—and everything we have done since our founding in 1994—helps people with Duchenne live longer, stronger lives. We will not rest until every person has a treatment to end Duchenne.
We invest deeply in treatments for this generation of people affected by Duchenne and in research that will benefit future generations. We advocate in Washington, DC, and have secured hundreds of millions of dollars in funding. We demand optimal care, and we strengthen, unite and educate the global Duchenne community.
Everything we do—and everything we have done since our founding in 1994—helps people with Duchenne live longer, stronger lives. We will not rest until every person has a treatment to end Duchenne.
Overview
Location
United States, New Jersey, Hackensack
Employees
201-500
Founded date
1994
Mentions in press and media 25
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 19, 2026 | Spot Biosystems Launches With $40 Million Financing For Non-Viral Gene Therapy Platform | Spot Biosystems announced its launch from stealth with $40 million in venture financing, along with preclinical research published in Nature Biomedical Engineering and an ongoing first-in-human clinical trial for Duchenne muscular dystrophy... |
| Jan 15, 2025 | Increasing Participation in Muscular Dystrophy Clinical Trials | Michel van Harten M.D., CEO of myTomorrows Muscular Dystrophy (MD) refers to a group of rare genetic conditions that cause progressive muscle weakness and degeneration in patients. Some forms of MD, such as Duchenne Muscular Dystrophy (DMD)... |
| Jun 20, 2024 | PPMD Applauds FDA Decision to Expand ELEVIDYS Label for Ages Four Years and Older | WASHINGTON, June 20, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), applauds the U.S. Food and Drug Administration (FDA) for its decis... |
| May 13, 2024 | Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | –Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned with FDA on Demonstration of Non-Clinical... |
| Apr 29, 2024 | Parent Project Muscular Dystrophy Awards $250,000 to Support Clinical Research Network for Duchenne Babies Identified by Newborn Screening | WASHINGTON, April 29, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is excited to announce a $250,000 award to Bo Hoon Lee, MD, from ... |
| May 11, 2023 | Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update | /EIN News/ -- -Enrollment Continues to Progress in HOPE-3, the Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy (DMD); On Track to Report Interim Analysis in Fourth Quarter of 2023- -Plan to Present 24-Month HOPE-2 Open Lab... |
| Nov 8, 2022 | Austin-Based Inspirational Hip Hop Artist With Duchenne Muscular Dystrophy To Host “Ryan’s Day” Annual Concert & Family Fun Event – Sun. Nov. 13th, 2022 | "Inspiration on Wheelz" is committed to raising public awareness through education, music, and annual event "Ryan's Day" to help find a cure for Duchenne Muscular Dystrophy. “As long as Ryan goes on, we go on, and the sh... |
| Dec 21, 2021 | Aldeyra shares spiral after a late-stage failure in dry eye disease — but that won't stop its pursuit of an NDA | Aldeyra Therapeutics’ shares tanked in premarket trading after the company admitted its dry eye candidate reproxalap missed the primary endpoint in a topline Phase III readout — but who needs the primary? Despite the l... |
| Dec 21, 2021 | One of Pfizer’s Duchenne gene therapy trials put on hold in wake of patient death as high-dose AAV concerns still cloud field | A young man with Duchenne muscular dystrophy has died in Pfizer’s Phase Ib trial of its mini-dystrophin gene therapy, triggering a halt in screening and dosing — and a clinical hold imposed by the FDA. Pfizer informed t... |
Show more
Reviews 0
FAQ about Parent Project Muscular Dystrophy (PPMD)
When was Parent Project Muscular Dystrophy (PPMD) founded?
Parent Project Muscular Dystrophy (PPMD) was founded in 1994.
What has the press written about Parent Project Muscular Dystrophy (PPMD)?
Parsers VC has collected 25 articles mentioning Parent Project Muscular Dystrophy (PPMD), among them “Spot Biosystems Launches With $40 Million Financing For Non-Viral Gene Therapy Platform” (Jun 19, 2026) and “Increasing Participation in Muscular Dystrophy Clinical Trials” (Jan 15, 2025).
Is Parent Project Muscular Dystrophy (PPMD) still active?
Yes, Parent Project Muscular Dystrophy (PPMD) is active; its latest activity on Parsers VC dates from Jul 30, 2026.